Carl Chiang

1.2k total citations · 1 hit paper
14 papers, 844 citations indexed

About

Carl Chiang is a scholar working on Molecular Biology, Psychiatry and Mental health and Cognitive Neuroscience. According to data from OpenAlex, Carl Chiang has authored 14 papers receiving a total of 844 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Psychiatry and Mental health and 4 papers in Cognitive Neuroscience. Recurrent topics in Carl Chiang's work include Dementia and Cognitive Impairment Research (5 papers), Neural dynamics and brain function (3 papers) and Visual perception and processing mechanisms (2 papers). Carl Chiang is often cited by papers focused on Dementia and Cognitive Impairment Research (5 papers), Neural dynamics and brain function (3 papers) and Visual perception and processing mechanisms (2 papers). Carl Chiang collaborates with scholars based in United States, Switzerland and Spain. Carl Chiang's co-authors include Peter König, Astrid von Stein, Ann M. Saunders, Conn Harrington, Michael C. Irizarry, Marina Zvartau‐Hind, Sharon Sawchak, Maike Gold, C H van Dyck and J. Davies and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Neurology and Behavioral and Brain Sciences.

In The Last Decade

Carl Chiang

12 papers receiving 818 citations

Hit Papers

Top-down processing mediated by interareal synchronization 2000 2026 2008 2017 2000 100 200 300 400 500

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carl Chiang United States 7 595 163 150 77 65 14 844
João Castelhano Portugal 18 323 0.5× 151 0.9× 117 0.8× 111 1.4× 57 0.9× 67 819
Ana Cervera‐Ferri Spain 15 232 0.4× 193 1.2× 221 1.5× 109 1.4× 104 1.6× 26 803
Negin Holland United Kingdom 16 286 0.5× 215 1.3× 215 1.4× 83 1.1× 130 2.0× 33 790
Ralf Müller Germany 12 303 0.5× 154 0.9× 82 0.5× 99 1.3× 182 2.8× 32 595
Nazan Dolu Türkiye 13 324 0.5× 134 0.8× 115 0.8× 84 1.1× 116 1.8× 56 630
Ottavia Dipasquale United Kingdom 20 561 0.9× 126 0.8× 134 0.9× 80 1.0× 151 2.3× 55 979
Masaru Ishibashi Japan 14 250 0.4× 215 1.3× 181 1.2× 163 2.1× 28 0.4× 21 737
Hideaki Mitani Japan 14 271 0.5× 189 1.2× 137 0.9× 135 1.8× 106 1.6× 18 856
Roxanne Sterniczuk Canada 11 227 0.4× 161 1.0× 311 2.1× 66 0.9× 64 1.0× 15 696

Countries citing papers authored by Carl Chiang

Since Specialization
Citations

This map shows the geographic impact of Carl Chiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carl Chiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carl Chiang more than expected).

Fields of papers citing papers by Carl Chiang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carl Chiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carl Chiang. The network helps show where Carl Chiang may publish in the future.

Co-authorship network of co-authors of Carl Chiang

This figure shows the co-authorship network connecting the top 25 collaborators of Carl Chiang. A scholar is included among the top collaborators of Carl Chiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carl Chiang. Carl Chiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Domínguez‐González, Cristina, Carl Chiang, Anny‐Odile Colson, et al.. (2025). Pyrimidine Nucleos(t)ide Therapy in Patients With Thymidine Kinase 2 Deficiency. Neurology. 105(6). e213908–e213908.
2.
Domínguez‐González, Cristina, R. Haas, Carmen Paradas, et al.. (2025). 71PSafety of pyrimidine nucleos(t)ide therapy in Thymidine kinase 2 deficiency: an integrated analysis from a pooled dataset. Neuromuscular Disorders. 53. 105852–105852.
3.
Burns, Daniel K., Carl Chiang, Kathleen A. Welsh‐Bohmer, et al.. (2019). The TOMMORROW study: Design of an Alzheimer's disease delay‐of‐onset clinical trial. Alzheimer s & Dementia Translational Research & Clinical Interventions. 5(1). 661–670. 30 indexed citations
4.
Alexander, Robert, Daniel K. Burns, Kathleen A. Welsh‐Bohmer, et al.. (2019). DT‐02‐02: TOMMORROW: RESULTS FROM A PHASE 3 TRIAL TO DELAY THE ONSET OF MCI DUE TO AD AND QUALIFY A GENETIC BIOMARKER ALGORITHM. Alzheimer s & Dementia. 15(7S_Part_28). 3 indexed citations
5.
Romero, Heather, Andreas U. Monsch, Kathleen M. Hayden, et al.. (2018). TOMMORROW neuropsychological battery: German language validation and normative study. Alzheimer s & Dementia Translational Research & Clinical Interventions. 4(1). 314–323. 10 indexed citations
6.
Budur, Kumar, Kathleen A. Welsh‐Bohmer, Daniel K. Burns, et al.. (2014). P4‐073: A PHARMACOGENETICS‐SUPPORTED CLINICAL TRIAL TO DELAY ONSET OF MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE USING LOW‐DOSE PIOGLITAZONE: AN UPDATE ON THE TOMORROW STUDY. Alzheimer s & Dementia. 10(4S_Part_22). 3 indexed citations
7.
Roses, Allen D., Kathleen A. Welsh‐Bohmer, Daniel K. Burns, et al.. (2013). P4–065: A pharmacogenetics‐supported clinical trial to delay onset of mild cognitive impairment due to Alzheimer's disease. Alzheimer s & Dementia. 9(4S_Part_18). 1 indexed citations
8.
Welsh‐Bohmer, Kathleen A., Heather Romero, Kathleen M. Hayden, et al.. (2013). O1–06–01: Challenges in international clinical trials to delay early symptomatic Alzheimer's disease. Alzheimer s & Dementia. 9(4S_Part_3). 4 indexed citations
9.
Roses, Allen D., Kathleen A. Welsh‐Bohmer, Daniel K. Burns, et al.. (2012). P4‐269: A pharmacogenetic‐supported clinical trial to delay onset of mild cognitive impairment (MCI) due to Alzheimer's disease (AD). Alzheimer s & Dementia. 8(4S_Part_20). 9 indexed citations
10.
Harrington, Conn, Sharon Sawchak, Carl Chiang, et al.. (2011). Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies. Current Alzheimer Research. 8(5). 592–606. 157 indexed citations
12.
Stein, Astrid von, et al.. (2000). Bi-directional interactions between visual areas in the awake behaving cat. Neuroreport. 11(4). 689–692. 38 indexed citations
13.
Stein, Astrid von, Carl Chiang, & Peter König. (2000). Top-down processing mediated by interareal synchronization. Proceedings of the National Academy of Sciences. 97(26). 14748–14753. 581 indexed citations breakdown →
14.
König, Peter, Carl Chiang, & Astrid von Stein. (1997). Internal context and top-down processing. Behavioral and Brain Sciences. 20(4). 691–692. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026